HealthcareServices

Mental Health Clinical Trials Industry Poised for Rapid Growth, Forecast to Touch $4.88 Billion by 2030 at 8.6% CAGR

March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the mental health clinical trials market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Mental Health Clinical Trials Market between 2026 and 2030?

The mental health clinical trials market size has shown strong growth in recent years. It is anticipated to increase from $3.23 billion in 2025 to $3.52 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.9%. This historical growth can be attributed to several factors: the increasing prevalence of mental health disorders, the expansion of pharmaceutical research pipelines, growing awareness of mental health conditions, rising clinical research funding, and the increasing use of standardized diagnostic criteria.

The mental health clinical trials market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $4.89 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.6%. Several factors are expected to drive this growth during the forecast period, including the increasing integration of digital mental health interventions, greater investment in personalized psychiatry research, the broadening of global mental health trial networks, enhanced regulatory encouragement for novel trial designs, and the expanded application of data-driven outcome assessments. Key trends for the forecast period encompass the growing embrace of decentralized clinical trial frameworks, the rising utilization of digital therapeutics within trials, increased incorporation of AI-powered patient recruitment tools, wider implementation of remote patient monitoring in studies, and a heightened emphasis on generating real-world evidence.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27343&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Mental Health Clinical Trials Market?

The escalating occurrence of mental health conditions is anticipated to drive the future expansion of the mental health clinical trials market. These conditions are characterized by significant effects on an individual’s emotions, thought processes, behavior, and overall psychological functioning. The increase in mental health disorders is attributed to heightened stress from modern lifestyles, including work pressures, social isolation, and continuous digital connectivity. Mental health clinical trials play a crucial role in advancing care by assessing the safety and effectiveness of new drugs, therapies, and behavioral interventions for these conditions. For example, in May 2024, the American Psychiatric Association, a US-based non-profit organization, reported that about 43% of adults in the USA felt more anxious in 2024, which is an increase from 37% in 2023 and 32% in 2022. Thus, the increasing prevalence of mental health disorders is a significant factor propelling the growth of the mental health clinical trials market.

What Segments Are Included Within The Mental Health Clinical Trials Market?

The mental health clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Study Design: Interventional, Observational, Other Study Designs

3) By Disorder: Anxiety Disorders, Depression, Bipolar Affective Disorder, Dissociation And Dissociative Disorders, Schizophrenia, Other Disorders

4) By Sponsor: Pharmaceutical And Biopharmaceutical Companies, Government Agencies, Other Sponsors

Subsegments:

1) By Phase I: Single Ascending Dose, Multiple Ascending Dose, First In Human, Pharmacokinetics Studies

2) By Phase II: Dose Ranging Studies, Proof Of Concept Studies, Randomized Controlled Trials, Open Label Studies

3) By Phase III: Large Scale Randomized Trials, Multicenter Studies, Comparative Effectiveness Trials, Double Blind Studies

4) By Phase IV: Post Marketing Surveillance, Long Term Safety Studies, Real World Evidence Studies, Pharmacovigilance Studies

Which Trends Are Shaping Activity Within The Mental Health Clinical Trials Market?

Leading companies in the mental-health clinical trials market are increasingly concentrating on developing innovative solutions, such as software-enhanced drug therapies, to boost treatment efficacy, personalize patient care, and improve real-world therapeutic outcomes. These software-enhanced drug therapies combine traditional medications with clinically validated therapeutic software, aiming to enhance patient results by tailoring care, improving adherence, and offering real-time behavioral or symptom-management support. For example, in October 2024, Click Therapeutics Inc., a US-based digital therapeutics company, introduced Click SE. This new offering is designed to pioneer software-enhanced drug therapies that integrate prescription software with pharmacotherapy to deliver additional clinical benefits and enable novel endpoints in mental-health clinical development. Click SE is a software-centric product family, consisting of regulated mobile and cloud applications built on Click’s AI-enabled DTx platform. It functions by providing structured therapeutic programs, real-time symptom monitoring, and medication-specific digital support, all crafted to work in synergy with a co-prescribed drug. Its unique features include adaptive algorithms that customize content to patient responses, integration pathways for pharmacologic dosing schedules, and embedded metrics for objective trial endpoints. Applications range from augmenting antipsychotics for negative symptoms and serving as adjunctive therapy in depression to providing support in substance-use disorders.

Who Are The Primary Competitors In The Global Mental Health Clinical Trials Market?

Major companies operating in the mental health clinical trials market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials, Inc., Ergomed, Celerion Inc., Biotrial S.A.S., Lindus Health Ltd., Novotech Health Holdings Pte Ltd., Precision for Medicine Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/mental-health-clinical-trials-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Mental Health Clinical Trials Market?

North America was the largest region in the mental health clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mental health clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Mental Health Clinical Trials Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27343&type=smp

Browse Through More Reports Similar to the Global Mental Health Clinical Trials Market 2026, By The Business Research Company

Iot In Elevators Market Report 2026

https://www.thebusinessresearchcompany.com/report/iot-in-elevators-global-market-report

Elevator And Escalator Market Report 2026

https://www.thebusinessresearchcompany.com/report/elevator-and-escalator-global-market-report

Smart Elevators Market Report 2026

https://www.thebusinessresearchcompany.com/report/smart-elevators-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795